Immunogenicity of tetravalent rhesus rotavirus vaccine administered with buffer and oral polio vaccine
- PMID: 1650128
- DOI: 10.1001/archpedi.1991.02160080070023
Immunogenicity of tetravalent rhesus rotavirus vaccine administered with buffer and oral polio vaccine
Abstract
Between January and November 1989, we studied 174 infants aged 6 to 16 weeks in a randomized clinical trial to (1) determine the immunogenicity of a single dose of tetravalent rhesus rotavirus vaccine (RRV-TV) when administered with three different buffer regimens: no antacid buffer and small-volume (2.5-mL) and large-volume (30-mL) antacid buffer; and (2) examine the potential interference of RRV-TV on the immune response to oral polio vaccine. Immunogenicity of RRV-TV, measured as a fourfold rise in antibody titers to rotavirus, was similar in the groups receiving small- and large-dose buffer (45% and 49%, respectively) and significantly less in the group that received RRV-TV alone (23%). Administration of RRV-TV with oral polio vaccine did not significantly interfere with the neutralization response of oral polio vaccine poliovirus serotypes 1, 2, or 3, and overall, 29%, 87%, and 24% of the infants had a fourfold rise in titer to each serotype, respectively.
Similar articles
-
Simultaneous administration of rhesus rotavirus vaccine and oral poliovirus vaccine: immunogenicity and reactogenicity.Pediatr Infect Dis J. 1989 Oct;8(10):692-6. doi: 10.1097/00006454-198910000-00006. Pediatr Infect Dis J. 1989. PMID: 2554244 Clinical Trial.
-
Concurrent oral poliovirus and rhesus-human reassortant rotavirus vaccination: effects on immune responses to both vaccines and on efficacy of rotavirus vaccines. The US Rotavirus Vaccine Efficacy Group.J Infect Dis. 1996 Feb;173(2):306-13. doi: 10.1093/infdis/173.2.306. J Infect Dis. 1996. PMID: 8568290 Clinical Trial.
-
Immunogenicity and reactogenicity of rhesus rotavirus vaccine given in combination with oral or inactivated poliovirus vaccines and diphtheria-tetanus-pertussis vaccine.Trans R Soc Trop Med Hyg. 1991 Mar-Apr;85(2):292-6. doi: 10.1016/0035-9203(91)90061-3. Trans R Soc Trop Med Hyg. 1991. PMID: 1653474
-
Rotavirus vaccines and vaccination in Latin America.Rev Panam Salud Publica. 2000 Nov;8(5):305-31. doi: 10.1590/s1020-49892000001000002. Rev Panam Salud Publica. 2000. PMID: 11190969 Review.
-
Influence of breast-feeding and oral poliovirus vaccine on the immunogenicity and efficacy of rotavirus vaccines.J Infect Dis. 1996 Sep;174 Suppl 1:S107-11. doi: 10.1093/infdis/174.supplement_1.s107. J Infect Dis. 1996. PMID: 8752299 Review.
Cited by
-
Oral rotavirus vaccines: how well will they work where they are needed most?J Infect Dis. 2009 Nov 1;200 Suppl 1(0 1):S39-48. doi: 10.1086/605035. J Infect Dis. 2009. PMID: 19817613 Free PMC article. Review.
-
Rotavirus vaccine for preventing diarrhoea.Cochrane Database Syst Rev. 2004;2004(1):CD002848. doi: 10.1002/14651858.CD002848.pub2. Cochrane Database Syst Rev. 2004. PMID: 14973994 Free PMC article.
-
Overview of the Development, Impacts, and Challenges of Live-Attenuated Oral Rotavirus Vaccines.Vaccines (Basel). 2020 Jun 27;8(3):341. doi: 10.3390/vaccines8030341. Vaccines (Basel). 2020. PMID: 32604982 Free PMC article. Review.
-
Immunogenicity, safety and efficacy of tetravalent rhesus-human, reassortant rotavirus vaccine in Belém, Brazil.Bull World Health Organ. 1996;74(5):491-500. Bull World Health Organ. 1996. PMID: 9002329 Free PMC article. Clinical Trial.
-
Phase III randomized clinical studies to evaluate the immunogenicity, lot-to-lot consistency, and safety of ROTAVAC® liquid formulations (ROTAVAC 5C & 5D) and non-inferiority comparisons with licensed ROTAVAC® (frozen formulation) in healthy infants.Hum Vaccin Immunother. 2023 Dec 15;19(3):2278346. doi: 10.1080/21645515.2023.2278346. Epub 2023 Nov 15. Hum Vaccin Immunother. 2023. PMID: 37968237 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical